Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects.

Next Previous
Trial Profile

A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SPRING-1
  • Sponsors ViiV Healthcare

Most Recent Events

  • 30 Apr 2019 Results of post hoc analysis using VL data obtained from the timepoints shared by A5353, SPRING 1 and SINGLE trial published in the Journal of Antimicrobial Chemotherapy
  • 07 Mar 2019 Results assessing associated with HOMA-IR (homeostasis model of assessment -insulin resistance) and effect of dolutegravir over time from SPRING-1, STRIIVING, SWORD-1 and -2 trials presented at the 26th Conference on Retroviruses and Opportunistic Infections
  • 31 Oct 2018 Results comparing viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy using data from A5353, SPRING-1 and SINGLE (n=588) presented at the 14th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top